<p>日本生命全球投资者美洲公司在最近向美国证券交易委员会（SEC）披露的文件中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 3.3%。该公司在本季度购买了 1,420 股后，持有 44,680 股艾伯维的股票。截至其最近的 SEC 文件，日本生命全球投资者美洲公司在艾伯维的持股价值为 9,361,000 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p>其他几家对冲基金也增加或减少了在 ABBV 的持股。Narus Financial Partners LLC 在第一季度将其在艾伯维的持股增加了 25.3%。Narus Financial Partners LLC 现在拥有 1,988 股该公司的股票，价值 417,000 美元，此前在上个季度购买了 401 股。Highland Capital Management LLC 在第一季度将其在艾伯维的持股增加了 6.3%。Highland Capital Management LLC 现在拥有 46,853 股该公司的股票，价值 9,817,000 美元，此前在上个季度购买了 2,792 股。Weaver Capital Management LLC 在第一季度将其在艾伯维的持股增加了 3.9%。Weaver Capital Management LLC 现在拥有 8,240 股该公司的股票，价值 1,727,000 美元，此前在上个季度购买了 310 股。North Star Asset Management Inc.在第一季度将其在艾伯维的持股增加了 0.5%。North Star Asset Management Inc.现在拥有 161,320 股该公司的股票，价值 33,800,000 美元，此前在上个季度购买了 756 股。最后，Alpine Bank Wealth Management 在第一季度购买了艾伯维的新头寸，价值约为 3,879,000 美元。机构投资者持有该公司 70.23% 的股票。</p>
<h2>分析师评级升级与降级</h2>
<p>几家研究公司最近对 ABBV 进行了评论。大和资本市场将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并在 8 月 7 日的研究报告中设定了 214.00 美元的目标价。美国银行在 6 月 9 日的研究报告中将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。法国巴黎银行在 5 月 8 日的研究报告中将艾伯维的评级上调至 “持有”。最后，派珀·桑德勒在 8 月 12 日的研究报告中开始覆盖艾伯维，设定了 “增持” 评级和 231.00 美元的目标价。四位分析师对该股票给予了强烈买入评级，十六位给予了买入评级，六位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，艾伯维目前的平均评级为 “适度买入”，平均目标价为 214.95 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p><strong>获取我们最新的 ABBV 股票报告</strong></p>
<h2>艾伯维股价上涨 0.4%</h2>
<p>艾伯维股票在周五开盘价为 212.77 美元。该公司的市值为 3758.7 亿美元，市盈率为 101.32，市盈增长比率为 1.36，贝塔值为 0.53。艾伯维的 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该公司的 50 日移动平均价格为 197.13 美元，200 日移动平均价格为 194.04 美元。公司的债务与股本比率为 44.14，速动比率为 0.61，流动比率为 0.74。</p>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日发布了季度财报。该公司报告本季度每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。该公司本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，该公司的季度收入增长了 6.6%。在去年同期，该公司每股收益为 2.65 美元。股票研究分析师预测，艾伯维将在本财年发布每股收益 12.31 美元。</p>
<h2>艾伯维分红公告</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 8 月 15 日支付。7 月 15 日的股东获得了 1.64 美元的分红。该分红的除息日为 7 月 15 日。这代表着每年 6.56 美元的分红和 3.1% 的分红收益率。艾伯维的分红支付比率目前为 312.38%。</p>
<h2>艾伯维内部买卖情况</h2>
<p>在其他消息中，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。该股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。交易后，该执行副总裁持有 58,247 股该公司的股票，价值约为 11,562,611.97 美元。这代表着其持股减少了 18.58%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该公司的股票。该股票以 198.42 美元的平均价格出售，总交易额为 8,407,055.40 美元。交易完成后，该执行副总裁直接持有 177,292 股该公司的股票，价值约为 35,178,278.64 美元。该交易使其持股减少了 19.29%。该销售的披露信息可以在此找到。公司内部人士持有该公司 0.25% 的股票。</p>
<h2>艾伯维公司简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>什么是盈利惊喜？</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>什么是国债？</li>
<li>Daqo New Energy：太阳能垄断企业启动 1 亿美元回购</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Affirm 超越盈利预期，令空头变成信徒</li>
</ul>
<p><strong>想知道其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>日本生命全球投资者美洲公司在第一季度将其在艾伯维公司的股份增加了 3.3%，目前持有 44,680 股，价值 936 万美元。其他对冲基金也调整了在艾伯维的持股。分析师们已将艾伯维的评级上调，普遍评级为 “适度买入”，平均目标价为 214.95 美元。艾伯维报告第二季度每股收益为 2.97 美元，低于预期，但收入增长至 154.2 亿美元。该公司宣布季度股息为 1.64 美元，收益率为 3.1%</p>

<p>Nippon Life Global Investors Americas Inc. boosted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,680 shares of the company's stock after buying an additional 1,420 shares during the quarter. Nippon Life Global Investors Americas Inc.'s holdings in AbbVie were worth $9,361,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>日本生命全球投资者美洲公司在最近向美国证券交易委员会（SEC）披露的文件中表示，在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的股份增加了 3.3%。该公司在本季度购买了 1,420 股后，持有 44,680 股艾伯维的股票。截至其最近的 SEC 文件，日本生命全球投资者美洲公司在艾伯维的持股价值为 9,361,000 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in ABBV. Narus Financial Partners LLC lifted its stake in AbbVie by 25.3% in the first quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock valued at $417,000 after purchasing an additional 401 shares during the last quarter. Highland Capital Management LLC lifted its stake in AbbVie by 6.3% in the first quarter. Highland Capital Management LLC now owns 46,853 shares of the company's stock valued at $9,817,000 after purchasing an additional 2,792 shares during the last quarter. Weaver Capital Management LLC lifted its stake in AbbVie by 3.9% in the first quarter. Weaver Capital Management LLC now owns 8,240 shares of the company's stock valued at $1,727,000 after purchasing an additional 310 shares during the last quarter. North Star Asset Management Inc. lifted its stake in AbbVie by 0.5% in the first quarter. North Star Asset Management Inc. now owns 161,320 shares of the company's stock valued at $33,800,000 after purchasing an additional 756 shares during the last quarter. Finally, Alpine Bank Wealth Management purchased a new position in AbbVie in the first quarter valued at approximately $3,879,000. Institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金也增加或减少了在 ABBV 的持股。Narus Financial Partners LLC 在第一季度将其在艾伯维的持股增加了 25.3%。Narus Financial Partners LLC 现在拥有 1,988 股该公司的股票，价值 417,000 美元，此前在上个季度购买了 401 股。Highland Capital Management LLC 在第一季度将其在艾伯维的持股增加了 6.3%。Highland Capital Management LLC 现在拥有 46,853 股该公司的股票，价值 9,817,000 美元，此前在上个季度购买了 2,792 股。Weaver Capital Management LLC 在第一季度将其在艾伯维的持股增加了 3.9%。Weaver Capital Management LLC 现在拥有 8,240 股该公司的股票，价值 1,727,000 美元，此前在上个季度购买了 310 股。North Star Asset Management Inc.在第一季度将其在艾伯维的持股增加了 0.5%。North Star Asset Management Inc.现在拥有 161,320 股该公司的股票，价值 33,800,000 美元，此前在上个季度购买了 756 股。最后，Alpine Bank Wealth Management 在第一季度购买了艾伯维的新头寸，价值约为 3,879,000 美元。机构投资者持有该公司 70.23% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several research firms recently commented on ABBV. Daiwa Capital Markets upgraded AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 price objective on the stock in a research note on Thursday, August 7th. Bank of America upped their price objective on AbbVie to $204.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, June 9th. Citigroup upped their price objective on AbbVie to $205.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, June 11th. BNP Paribas upgraded AbbVie to a &#34;hold&#34; rating in a research report on Thursday, May 8th. Finally, Piper Sandler started coverage on AbbVie in a research report on Tuesday, August 12th. They set an &#34;overweight&#34; rating and a $231.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, AbbVie presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $214.95.</p>
<div class="lb-trans"><p>几家研究公司最近对 ABBV 进行了评论。大和资本市场将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并在 8 月 7 日的研究报告中设定了 214.00 美元的目标价。美国银行在 6 月 9 日的研究报告中将艾伯维的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。花旗集团在 6 月 11 日的研究报告中将艾伯维的目标价上调至 205.00 美元，并给予该公司 “持有” 评级。法国巴黎银行在 5 月 8 日的研究报告中将艾伯维的评级上调至 “持有”。最后，派珀·桑德勒在 8 月 12 日的研究报告中开始覆盖艾伯维，设定了 “增持” 评级和 231.00 美元的目标价。四位分析师对该股票给予了强烈买入评级，十六位给予了买入评级，六位对该公司的股票给予了持有评级。根据 MarketBeat 的数据，艾伯维目前的平均评级为 “适度买入”，平均目标价为 214.95 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 ABBV 股票报告</strong></p>
</div><h2>AbbVie Trading Up 0.4%</h2>
<div class="lb-trans"><h2>艾伯维股价上涨 0.4%</h2>
</div><p>AbbVie stock opened at $212.77 on Friday. The stock has a market cap of $375.87 billion, a P/E ratio of 101.32, a PEG ratio of 1.36 and a beta of 0.53. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The firm's fifty day moving average price is $197.13 and its 200-day moving average price is $194.04. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.</p>
<div class="lb-trans"><p>艾伯维股票在周五开盘价为 212.77 美元。该公司的市值为 3758.7 亿美元，市盈率为 101.32，市盈增长比率为 1.36，贝塔值为 0.53。艾伯维的 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该公司的 50 日移动平均价格为 197.13 美元，200 日移动平均价格为 194.04 美元。公司的债务与股本比率为 44.14，速动比率为 0.61，流动比率为 0.74。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.65 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日发布了季度财报。该公司报告本季度每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。该公司本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，该公司的季度收入增长了 6.6%。在去年同期，该公司每股收益为 2.65 美元。股票研究分析师预测，艾伯维将在本财年发布每股收益 12.31 美元。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>艾伯维分红公告</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a $1.64 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.1%. AbbVie's dividend payout ratio is presently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 8 月 15 日支付。7 月 15 日的股东获得了 1.64 美元的分红。该分红的除息日为 7 月 15 日。这代表着每年 6.56 美元的分红和 3.1% 的分红收益率。艾伯维的分红支付比率目前为 312.38%。</p>
</div><h2>Insider Buying and Selling at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维内部买卖情况</h2>
</div><p>In other news, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。该股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。交易后，该执行副总裁持有 58,247 股该公司的股票，价值约为 11,562,611.97 美元。这代表着其持股减少了 18.58%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。此外，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该公司的股票。该股票以 198.42 美元的平均价格出售，总交易额为 8,407,055.40 美元。交易完成后，该执行副总裁直接持有 177,292 股该公司的股票，价值约为 35,178,278.64 美元。该交易使其持股减少了 19.29%。该销售的披露信息可以在此找到。公司内部人士持有该公司 0.25% 的股票。</p>
</div><h2>AbbVie Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>What is an Earnings Surprise?</li>
<li>Why Marvell’s 19% Drop Could Be a Big Buy-the-Dip Opportunity</li>
<li>What Are Treasury Bonds?</li>
<li>Daqo New Energy: Solar Monopoly Launches $100M Buyback</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Affirm Crushes Earnings Expectations, Turns Bears into Believers</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>什么是盈利惊喜？</li>
<li>为什么 Marvell 的 19% 下跌可能是一个很好的买入机会</li>
<li>什么是国债？</li>
<li>Daqo New Energy：太阳能垄断企业启动 1 亿美元回购</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Affirm 超越盈利预期，令空头变成信徒</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

日本生命全球投资者美洲公司增持了艾伯维公司的股份 $ABBV